D Rebecca Prevots

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7343405/publications.pdf

Version: 2024-02-01

92 papers 6,605 citations

66343 42 h-index 79 g-index

92 all docs 92 docs citations

92 times ranked 5837 citing authors

#	Article	IF	Citations
1	Nontuberculous mycobacterial infection and environmental molybdenum in persons with cystic fibrosis: a case–control study in Colorado. Journal of Exposure Science and Environmental Epidemiology, 2022, 32, 289-294.	3.9	16
2	Nontuberculous Mycobacteria Infection Risk and Trace Metals in Surface Water: A Population-based Ecologic Epidemiologic Study in Oregon. Annals of the American Thoracic Society, 2022, 19, 543-550.	3.2	14
3	Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection. Current Medical Research and Opinion, 2022, 38, 273-275.	1.9	6
4	Tenets of a holistic approach to drinking water-associated pathogen research, management, and communication. Water Research, 2022, 211, 117997.	11.3	21
5	The 6-minute walk test predicts mortality in a pulmonary nontuberculous mycobacteria-predominant bronchiectasis cohort. BMC Infectious Diseases, 2022, 22, 75.	2.9	2
6	CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018. ERJ Open Research, 2022, 8, 00724-2021.	2.6	18
7	Nontuberculous mycobacterial pulmonary disease incidence among elderly patients with bronchiectasis. European Respiratory Journal, 2022, 59, 2200018.	6.7	1
8	HALT-ing Nontuberculous Mycobacteria in CF Centers. Is There Something in The Water?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	1
9	Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. Cell Host and Microbe, 2022, 30, 1020-1033.e6.	11.0	37
10	Invasive Candidiasis Species Distribution and Trends, United States, 2009–2017. Journal of Infectious Diseases, 2021, 223, 1295-1302.	4.0	51
11	Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009–2014. Emerging Infectious Diseases, 2021, 27, 845-852.	4.3	24
12	Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest, 2021, 160, 2042-2050.	0.8	3
13	Environmental predictors of pulmonary nontuberculous mycobacteria (NTM) sputum positivity among persons with cystic fibrosis in the state of Florida. PLoS ONE, 2021, 16, e0259964.	2.5	9
14	Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design. PLoS ONE, 2021, 16, e0261628.	2.5	10
15	Mycobacterial Testing Trends, United States, 2009–20151. Emerging Infectious Diseases, 2020, 26, 2243-2246.	4.3	11
16	Nontuberculous Mycobacterial Disease and Molybdenum in Colorado Watersheds. International Journal of Environmental Research and Public Health, 2020, 17, 3854.	2.6	18
17	Amikacin exposure and susceptibility of macrolide-resistant <i>Mycobacterium abscessus</i> Research, 2019, 5, 00154-2018.	2.6	6
18	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53

#	Article	IF	CITATIONS
19	Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) in the USA. Respiratory Medicine, 2019, , 145-161.	0.1	8
20	362. Species Distribution and Trends of Invasive Candidiasis in the United States, 2009–2015, Using a Large Electronic Medical Record Database. Open Forum Infectious Diseases, 2018, 5, S142-S142.	0.9	2
21	1720. Regional Differences in Trends of Hospitalizations Associated With Tick-Borne Diseases in the United States, 2009–2014. Open Forum Infectious Diseases, 2018, 5, S52-S53.	0.9	0
22	Hospital-based antibiotic use in patients with <i>Mycobacterium avium</i> complex. ERJ Open Research, 2018, 4, 00109-2018.	2.6	3
23	Sarcoidosis-associated Hospitalizations in the United States, 2002 to 2012. Annals of the American Thoracic Society, 2018, 15, 1490-1493.	3.2	9
24	Norovirus, astrovirus, and sapovirus among immunocompromised patients at a tertiary care research hospital. Diagnostic Microbiology and Infectious Disease, 2018, 92, 143-146.	1.8	27
25	Epidemiology of Nontuberculous Mycobacteriosis. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 325-335.	2.1	64
26	Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clinical Infectious Diseases, 2018, 67, 1803-1814.	5.8	234
27	Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010–2014. Annals of the American Thoracic Society, 2018, 15, 817-826.	3.2	113
28	Seroepidemiology of helminths and the association with severe malaria among infants and young children in Tanzania. PLoS Neglected Tropical Diseases, 2018, 12, e0006345.	3.0	7
29	Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. European Respiratory Journal, 2017, 49, 1601855.	6.7	94
30	Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. Annals of the American Thoracic Society, 2017, 14, 1120-1128.	3.2	17
31	Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. European Respiratory Journal, 2017, 49, 1700374.	6.7	50
32	Hemoglobin variants shape the distribution of malaria parasites in human populations and their transmission potential. Scientific Reports, 2017, 7, 14267.	3.3	25
33	Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009–2013. Annals of the American Thoracic Society, 2017, 14, 1655-1661.	3.2	75
34	Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerging Infectious Diseases, 2017, 23, 439-447.	4.3	80
35	Treatment Regimens Prescribed for Mycobacterium avium complex Infections Diagnosed in Hospitalized Patients throughout the United States, 2008–2013. Open Forum Infectious Diseases, 2017, 4, S676-S676.	0.9	0
36	A Malaria-Resistant Phenotype with Immunological Correlates in a Tanzanian Birth Cohort Exposed to Intense Malaria Transmission. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1190-1196.	1.4	5

#	Article	IF	CITATIONS
37	Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–20121. Emerging Infectious Diseases, 2016, 23, 7-13.	4.3	102
38	Species Distribution of Invasive Candidiasis, 2009–2013, United States. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
39	Long-term Follow-up of Patients With Lyme Disease: Longitudinal Analysis of Clinical and Quality-of-life Measures. Clinical Infectious Diseases, 2016, 62, 1546-1551.	5. 8	46
40	Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010–2013. Open Forum Infectious Diseases, 2016, 3, ofw169.	0.9	21
41	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Annals of the American Thoracic Society, 2016, 13, S379-S384.	3.2	58
42	Safety and Tolerability of Long Term Use of Tedizolid for Treatment of Nontuberculous Mycobacterial Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	16
43	Preparing for future efficacy trials of severe malaria vaccines. Vaccine, 2016, 34, 1865-1867.	3.8	2
44	Reply: Cure Not Possible, by Definition. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1256-1257.	5.6	2
45	The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. European Respiratory Journal, 2015, 45, 1177-1179.	6.7	62
46	Beyond Marfan: the clinical impact of bronchiectasis and non-tuberculous mycobacteria in connective tissue diseases. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1409-1409.	1.2	5
47	Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria. Clinics in Chest Medicine, 2015, 36, 13-34.	2.1	665
48	Spatial epidemiology of blastomycosis hospitalizations: detecting clusters and identifying environmental risk factors. Medical Mycology, 2015, 53, 447-454.	0.7	20
49	Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 618-628.	5.6	136
50	The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States. Annals of the American Thoracic Society, 2015, 12, 1458-1464.	3.2	123
51	Variable agreement among experts regarding <scp><i>M</i></scp> <i>ycobacterium avium</i> complex lung disease. Respirology, 2015, 20, 348-351.	2.3	17
52	Clonal Diversification and Changes in Lipid Traits and Colony Morphology in Mycobacterium abscessus Clinical Isolates. Journal of Clinical Microbiology, 2015, 53, 3438-3447.	3.9	48
53	Semiquantitative Culture Analysis during Therapy for <i>Mycobacterium avium</i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 754-760.	5.6	67
54	Opinions Differ by Expertise in Mycobacterium avium Complex Disease. Annals of the American Thoracic Society, 2014, 11, 17-22.	3.2	15

#	Article	IF	CITATIONS
55	Environmental Risks for Nontuberculous Mycobacteria. Individual Exposures and Climatic Factors in the Cystic Fibrosis Population. Annals of the American Thoracic Society, 2014, 11, 1032-1038.	3.2	67
56	Nontuberculous Mycobacteria among Patients with Cystic Fibrosis in the United States. Screening Practices and Environmental Risk. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 581-586.	5.6	119
57	Parasite Burden and Severity of Malaria in Tanzanian Children. New England Journal of Medicine, 2014, 370, 1799-1808.	27.0	139
58	Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. Annals of the American Thoracic Society, 2014, 11, 30-35.	3.2	156
59	Lack of Adherence to Evidence-based Treatment Guidelines for Nontuberculous Mycobacterial Lung Disease. Annals of the American Thoracic Society, 2014, 11, 9-16.	3.2	116
60	Incidence and Trends of Blastomycosis-Associated Hospitalizations in the United States. PLoS ONE, 2014, 9, e105466.	2.5	39
61	Molecular Epidemiology. , 2013, , 3-13.		0
62	Epidemiology of Nontuberculous Mycobacterial Infections and Associated Chronic Macrolide Use among Persons with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 807-812.	5.6	123
63	Epidemiology of Cryptococcal Meningitis in the US: 1997–2009. PLoS ONE, 2013, 8, e56269.	2.5	259
64	Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil. Emerging Infectious Diseases, 2013, 19, 393-9.	4.3	41
65	Cytokine Profiles at Birth Predict Malaria Severity during Infancy. PLoS ONE, 2013, 8, e77214.	2.5	19
66	Spatial Clusters of Nontuberculous Mycobacterial Lung Disease in the United States. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 553-558.	5 . 6	172
67	Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare Beneficiaries. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 881-886.	5.6	547
68	Trends in Bronchiectasis Among Medicare Beneficiaries in the United States, 2000 to 2007. Chest, 2012, 142, 432-439.	0.8	252
69	Molecular Epidemiology of Neisseria meningitidis Serogroup B in Brazil. PLoS ONE, 2012, 7, e33016.	2.5	37
70	Hospitalizations Associated with Disseminated Coccidioidomycosis, Arizona and California, USA. Emerging Infectious Diseases, 2012, 18, 1476-1479.	4.3	22
71	Trends and Burden of Bronchiectasis-Associated Hospitalizations in the United States, 1993-2006. Chest, 2010, 138, 944-949.	0.8	200
72	Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 970-976.	5.6	487

#	Article	IF	Citations
73	Nontuberculous Mycobacteria–associated Lung Disease in Hospitalized Persons, United States, 1998–2005. Emerging Infectious Diseases, 2009, 15, 1562-1569.	4.3	126
74	Pulmonary nontuberculous mycobacterial infections: Antibiotic treatment and associated costs. Respiratory Medicine, 2009, 103, 1448-1455.	2.9	84
75	Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital. Clinical Infectious Diseases, 2008, 46, 42-49.	5.8	94
76	PorA Variable Antigenic Regions VR1, VR2, and VR3 of Neisseria meningitidis Serogroups B and C Isolated in Brazil from 1999 to 2004. Infection and Immunity, 2007, 75, 3683-3685.	2.2	10
77	Filariasis in Travelers Presenting to the GeoSentinel Surveillance Network. PLoS Neglected Tropical Diseases, 2007, 1, e88.	3.0	86
78	Impact of rubella vaccination strategy on the occurrence of congenital rubella syndrome. Jornal De Pediatria, 2007, 83, 415-21.	2.0	3
79	Field Applicability of a Rapidâ€Format Anti–Ovâ€16 Antibody Test for the Assessment of Onchocerciasis Control Measures in Regions of Endemicity. Journal of Infectious Diseases, 2006, 194, 216-221.	4.0	83
80	Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United States. JAMA - Journal of the American Medical Association, 2004, 292, 1696.	7.4	180
81	Neonatal tetanus incidence in China, 1996-2001, and risk factors for neonatal tetanus, Guangxi Province, China. International Journal of Epidemiology, 2004, 33, 551-557.	1.9	28
82	Interruption of Measles Transmission in Brazil, 2000–2001. Journal of Infectious Diseases, 2003, 187, S111-S120.	4.0	31
83	Persistence of Vaccineâ€Derived Polioviruses among Immunodeficient Persons with Vaccineâ€Associated Paralytic Poliomyelitis. Journal of Infectious Diseases, 2003, 188, 1845-1852.	4.0	89
84	Burden of congenital rubella syndrome after a community-wide rubella outbreak, Rio Branco, Acre, Brazil, 2000 to 2001. Pediatric Infectious Disease Journal, 2003, 22, 323-329.	2.0	27
85	Incidence of HIV among injection drug users entering drug treatment programs in four US cities. Journal of Urban Health, 2001, 78, 152-161.	3.6	28
86	Pertussis outbreak in an elementary school with high vaccination coverage. Pediatric Infectious Disease Journal, 2001, 20, 1108-1112.	2.0	47
87	POLIOVIRUS VACCINES. Pediatric Clinics of North America, 2000, 47, 287-308.	1.8	27
88	Outbreak of Paralytic Poliomyelitis in Albania, 1996: High Attack Rate Among Adults and Apparent Interruption of Transmission Following Nationwide Mass Vaccination. Clinical Infectious Diseases, 1998, 26, 419-425.	5.8	57
89	Poliomyelitis Prevention in the United States: New Recommendations for Routine Childhood Vaccination Place Greater Reliance on Inactivated Poliovirus Vaccine. Pediatric Annals, 1997, 26, 378-383.	0.8	12
90	Completeness of Reporting for Paralytic Poliomyelitis, United States, 1980 Through 1991. JAMA Pediatrics, 1994, 148, 479.	3.0	81

ı	#	Article	IF	CITATIONS
	91	First Reported Outbreak of Classical Dengue Fever at 1,700 Meters above Sea Level in Guerrero State, Mexico, June 1988. American Journal of Tropical Medicine and Hygiene, 1992, 46, 649-653.	1.4	53
	92	Determinants and Predictors of Dengue Infection in Mexico. American Journal of Epidemiology, 1991, 133, 1168-1178.	3.4	145